The Discovery of Gadopiclenol: An Example of Rational Drug Design?

Area of Science:

• Medicinal Chemistry
• Radiopharmaceutical Development
• Diagnostic Imaging

Background:

• Gadopiclenol was initially developed as a high-relaxivity MRI contrast agent.
• Design considerations included physicochemical properties, pharmacokinetics, toxicity, and complex stability.
• The initial prototype underwent modifications due to safety concerns like nephrogenic systemic fibrosis.

Purpose of the Study:

• To detail the rational, multiparametric molecular design of gadopiclenol.
• To explain the evolution of gadopiclenol's drug target profile and medical positioning.
• To highlight the application of property-based drug design in developing diagnostic agents.

Main Methods:

• Rational molecular design based on a gadolinium complex with specific structural features (macrocyclic, nonionic, steric constraints, hydrophilic arms).
• Modification of an initial prototype (P03277V1) through an isomerization process to enhance stability and reduce costs.
• Evaluation of physicochemical properties, stability, and safety profiles.

Main Results:

• Gadopiclenol was created with a macrocyclic, nonionic structure, steric constraints, and hydrophilic pendant arms for improved safety and efficacy.
• An isomerization process led to gadopiclenol with excellent kinetic stability.
• The agent's medical positioning shifted towards lower doses (0.05 mmol/kg) to minimize gadolinium exposure and associated risks.

Conclusions:

• Gadopiclenol's development exemplifies property-based drug design, comparable in complexity to therapeutic agent design.
• The evolution of gadopiclenol demonstrates the dynamic nature of medical positioning during clinical development.
• Current use at a reduced dose prioritizes patient safety, with future potential for higher doses to enhance diagnostics.